🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

#TumorBoardTuesday 🧑🏾‍🏫We have👂🏻a lot about EV + pembro as1⃣st line Tx for #BladderCancer 🤔But what Tx do you use upon progression❓ 📢Join us Tuesday, 08-20-24 at 8PM ET as Shilpa Gupta & Jon Anker, MD, PhD🗣️2L TX following progression on EV + pembro RT and bring others into the🗣️‼️

#TumorBoard ➡️This will be a robust🗣️lead by Shilpa Gupta & Jon Anker, MD, PhD on 2L TX following progression on enfortumab vedotin + pembrolizumab for #BladderCancer 📣Join us tomorrow‼️

Shilpa Gupta Jon Anker, MD, PhD Integrity CE, LLC #PreTest Q1️⃣ #TumorBoardTuesday Free #CME integrityce.com/TBT2024 🤔Which 2L Tx would you offer a 45yo♂️ with mUC, 🧬FGFR3 WT, 🔬HER2 IHC 2+, whose disease has progressed after 6 cycles EV+P, and who developed grade 2 neuropathy with EV❓

Shilpa Gupta Jon Anker, MD, PhD Integrity CE, LLC #PreTest Q2⃣#TumorBoardTuesday Free #CME integrityce.com/TBT2024 🧐A 68yo♂️with 3B CKD receives 1L EV+P for🧬FGFR3 S249C-mutated mUC ✅He achieves PR then discontinues EV due to neuropathy 🩻Scans reveal progression after 4 mos of pembro ➡️Which 2L therapy do you recommend❓

🎉Congratulations🥳 Bhardwaj Lab Dr. Nina Bhardwaj, elected to National Academy of Medicine for advancing our understanding of human dendritic cell cross-presentation pathways and adjuvanticity, ‘pivotal discoveries which underlie the first approval of a cell-based vaccine in cancer.’

#TumorBoardTuesday Matt Galsky 1/27 #TumorBoardTuesday #OncTwitter Your patient presents for follow up: 68 year old 👨 with no significant PMH except urothelial cancer 📖  Previously treated with cystectomy ➡️ adjuvant gem/cis ‼️ Metastatic nodal recurrence detected via ctDNA and PET after 6 months

Cancer vaccines are no longer a distant dream—they’re becoming a pivotal tool in the fight against cancer. When @STATNews highlighted scientific leaders at the forefront, two PICI Investigators stood out: Drs. Catherine Wu of Dana-Farber & Nina Bhardwaj of Icahn School of Medicine at Mount Sinai. (1/2)

Congratulations to Nina Bhardwaj, MD, PhD, elected to National Academy of Medicine for contributions to cancer immunotherapy! bit.ly/4el8rPH Bhardwaj Lab Icahn School of Medicine at Mount Sinai #Cancer National Academy of Medicine

PD-L1 testing has correlated inconsistently with outcomes with PD-1/PD-L1 blockade in urothelial cancer. Lack of uniform assays for PD-L1 IHC have been viewed as a shortcoming but can these differences teach us about biology? Uromigos aacrjournals.org/cancerimmunolr…

Differential PD-L1 staining between IHC assays may explain inconsistent outcomes with PD-L1 status - SP142 detects mature DCs > favorable outcomes - 22C3 detects tumor + immune - Tumor cell-predominant PD-L1+ > poor outcomes shorturl.at/WUClw Icahn School of Medicine at Mount Sinai The Tisch Cancer Institute

Congratulations Dr. Nina Bhardwaj !

PGV001, a multi-peptide personalized neoantigen vaccine platform: Phase I study in patients with solid and hematological malignancies in the adjuvant setting aacrjournals.org/cancerdiscover… Bhardwaj Lab Thomas Marron, MD, PhD Icahn School of Medicine at Mount Sinai

Congratulations to several members of our Vaccine and Cell Therapy Laboratory, past and present, on the publication of our PGV neoantigen vaccine trial data in Cancer Discovery! 🥳

Priority Brief: Different PD-L1 Assays Reveal Distinct Immunobiology and Clinical Outcomes in Urothelial Cancer brnw.ch/21wRWwe Matt Galsky The Tisch Cancer Institute Sanjeev Mariathasan @Drenriquegrande Ian Davis @RoBanche JA Arranz

Different PD-L1 Assays Reveal Distinct Immunobiology and Clinical Outcomes in Urothelial Cancer aacrjournals.org/cancerimmunolr… Study investigates the variability in PD-L1 immunohistochemistry (IHC) assays used to predict immune checkpoint blockade (ICB) response in urothelial cancer,

We tested the feasibility and immunogenicity of a personalized neoantigen vaccine + PD-L1 blockade in #bladdercancer including the adjuvant setting. nature.com/articles/s4301… Jon Anker, MD, PhD Bhardwaj Lab UroToday.com Uromigos The Tisch Cancer Institute Dr. Bishoy M. Faltas Nature Cancer Bladder Cancer Advocacy Network

Atezolizumab plus personalized neoantigen vaccination in urothelial cancer: a phase 1 trial OUT ON nature Cancer nature.com/articles/s4301… Study evaluated the feasibility and safety of combining atezolizumab, an anti–PD-L1 immune checkpoint inhibitor, with PGV001, a personalized

Saxena, Anker, Kodysh et al. demonstrated that the personalized long-peptide neoantigen vaccine PGV001, in combination with atezolizumab, was feasible, safe, and elicited durable neoantigen-specific T cell [...] bit.ly/3T6h5cq  Icahn School of Medicine at Mount Sinai  Julia Kodysh  Matt Galsky